Clinical Trial Detail

NCT ID NCT04087174
Title A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca

prostate cancer


Abiraterone + Capivasertib

Capivasertib + Enzalutamide

Age Groups: adult senior

No variant requirements are available.